Acute and Subacute Endocarditis DRG Reimbursement Guide

DRG 290 pertains to acute and subacute infective endocarditis cases without a Complication or Comorbidity or Major Complication or Comorbidity, covering inpatient medical and surgical management of heart valve or endocardial infections. Accurate assignment of this Diagnosis-Related Group is important for Medicare inpatient reimbursement because it determines the bundled payment level for stays without higher-severity complications.

DRG 290 Overview

DRG 290 covers acute and subacute infective endocarditis cases without a Complication or Comorbidity or Major Complication or Comorbidity, typically involving inpatient medical or surgical management for infection of the heart valves or endocardial surface. This Diagnosis-Related Group matters for Medicare payment because it groups patients with similar clinical resource needs, driving the base payment rate for the inpatient stay. Hospitals receive a bundled reimbursement based on the assigned Diagnosis-Related Group, so accurate clinical coding and documentation determine payment eligibility and grouping. The classification excludes patients with additional coded complications that would move the case to higher-severity Diagnosis-Related Groups.

DRG 290 Overview

Early antimicrobial strategy trials: studies that compare different initial intravenous antibiotic regimens, dosing strategies, or durations in adults hospitalized with acute or subacute bacterial endocarditis who do not have major comorbid complications (no CC/MCC). These trials enroll patients at presentation to evaluate time to bacteremia clearance, need for escalation of care (e.g., transfer to ICU or surgery), and adverse events related to therapy. Results inform inpatient treatment pathways, antibiotic stewardship, length of stay, and expected acute resource use that are critical for clinical teams and hospital payers managing DRG 290 cases.
Comparative effectiveness of surgical versus conservative management in non-complicated endocarditis: observational cohort studies or pragmatic trials that examine outcomes for patients without major complications who are managed medically versus those referred for valve repair/replacement during the same admission. These studies focus on 30‑ and 90‑day mortality, readmissions, functional status, and in‑hospital resource utilization, stratified by pathogen, valve involved, and embolic risk. Findings guide decisions about surgical referral thresholds and allocation of inpatient surgical resources, impacting reimbursement, length of stay, and expected post-acute care needs under this DRG.
Post-discharge outcomes and care transition studies: prospective studies following patients discharged after treatment for acute/subacute endocarditis without CC/MCC to evaluate readmission rates, adherence to outpatient parenteral antimicrobial therapy (OPAT), complication detection, and coordination with primary care and cardiology. These investigations identify predictors of readmission, monitor adverse events from prolonged outpatient antibiotics, and test models of post-discharge follow-up (e.g., nurse‑led clinics or telehealth). For providers and payers, this research addresses preventable readmissions, continuity of care, and cost drivers after the index hospitalization captured by DRG 290.

Early antimicrobial strategy trials: studies that compare different initial intravenous antibiotic regimens, dosing strategies, or durations in adults hospitalized with acute or subacute bacterial endocarditis who do not have major comorbid complications (no CC/MCC). These trials enroll patients at presentation to evaluate time to bacteremia clearance, need for escalation of care (e.g., transfer to ICU or surgery), and adverse events related to therapy. Results inform inpatient treatment pathways, antibiotic stewardship, length of stay, and expected acute resource use that are critical for clinical teams and hospital payers managing DRG 290 cases.
Comparative effectiveness of surgical versus conservative management in non-complicated endocarditis: observational cohort studies or pragmatic trials that examine outcomes for patients without major complications who are managed medically versus those referred for valve repair/replacement during the same admission. These studies focus on 30‑ and 90‑day mortality, readmissions, functional status, and in‑hospital resource utilization, stratified by pathogen, valve involved, and embolic risk. Findings guide decisions about surgical referral thresholds and allocation of inpatient surgical resources, impacting reimbursement, length of stay, and expected post-acute care needs under this DRG.
Post-discharge outcomes and care transition studies: prospective studies following patients discharged after treatment for acute/subacute endocarditis without CC/MCC to evaluate readmission rates, adherence to outpatient parenteral antimicrobial therapy (OPAT), complication detection, and coordination with primary care and cardiology. These investigations identify predictors of readmission, monitor adverse events from prolonged outpatient antibiotics, and test models of post-discharge follow-up (e.g., nurse‑led clinics or telehealth). For providers and payers, this research addresses preventable readmissions, continuity of care, and cost drivers after the index hospitalization captured by DRG 290.

OpenPayer

Acute and Subacute Endocarditis without CC/MCC: Inpatient Reimbursement Overview

Sign up for drg 290 policy alerts

DRG 290 Overview

OpenPayer

Acute and Subacute Endocarditis without CC/MCC: Inpatient Reimbursement Overview

Sign up for drg 290 policy alerts

DRG 290 Overview

Clinical Trials

Related Codes

References

Clinical Trials

Related Codes

References